Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06559163 · ClinicalTrials.gov registry record · Phase 2
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
A Phase 2 study of Systemic Lupus Erythematosus, sponsored by Zenas BioPharma (USA).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
- 20
- Study locations
NCT06559163: Recruiting Phase 2 study of Systemic Lupus Erythematosus, sponsored by Zenas BioPharma (USA).
NCT06559163 is a Phase 2 study of Systemic Lupus Erythematosus that is actively recruiting participants, run by Zenas BioPharma (USA). The registered enrollment target is 190 participants, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06559163, a Phase 2 study of Systemic Lupus Erythematosus, is actively recruiting participants, sponsored by Zenas BioPharma (USA).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).
Primary Outcome
Proportion of patients who achieve a response according to the BILAG-Based Composite Lupus Assessment (BICLA) Response
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Obexelimab
Study Locations (20)
California
- Sierra Pacific Arthritis and Rheumatology Centers - Fresno
- California Research Institute - Huntington Park
- University of California, San Diego - La Jolla
Michigan
- Henry Ford Hospital - Detroit
- June DO, PC - Lansing
- Juno DO, PC - Lansing
Texas
- Prolato Clinical Research Center (PCRC) - Houston
- Accurate Clinical Research - Houston
- Prime Clinical Research - Mansfield - Mansfield
Other
- CHU de Liege - Liège
- Medical Center Medtech Services EOOD - Haskovo
- University Multiprofile Hospital for Active Treatment "Eurohospital Plovdiv" - Plovdiv
Florida
- Clinical Research of West Florida, Inc - Clearwater
- Clinical Research of West Florida, Inc. - Tampa
Georgia
- Emory University - Atlanta
Louisiana
- Accurate Clinical Research - Lake Charles
North Carolina
- DJL Clinical Research PLLC - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2024-09-17 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What NCT06559163 shows while recruiting
NCT06559163 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06559163 names 20 study sites across 11 states, led by California, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT06559163 about?
NCT06559163 is a clinical study titled "A Study of Obexelimab in Patients With Systemic Lupus Erythematosus". This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).
What is the current status of trial NCT06559163?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2024-09-17. Estimated completion is 2026-09.
What conditions does trial NCT06559163 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT06559163?
The interventions under investigation include: Placebo (DRUG), Obexelimab (DRUG).
Who is sponsoring clinical trial NCT06559163?
This trial is sponsored by Zenas BioPharma (USA), which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06559163 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06559163's enrollment target sits among peer trials
190 43rd of 99 higher than 57 of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
RECRUITING · Phase 2
-
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
RECRUITING · Phase 2
-
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
RECRUITING · Phase 2
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03257033 · 190 participants · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI